Disgruntled Takeda alumni demand a window into $62B Shire buy

Takeda HQ
Shareholders are asking Takeda for more transparency around its Shire deal, and they want a response by Oct. 31. (Takeda)

It’s no secret that Takeda’s pending Shire megadeal has plenty of critics, and some of them have penned a letter to company president Christophe Weber demanding behind-the-scenes information and documents to justify the buy.

The group of about 130 shareholders, including alumni of the Japanese drugmaker, requested that Weber serve up details on how Takeda plans to pay down the debt it’ll incur with the $62 billion acquisition. It also wants to know why Takeda offered a 65% premium for the rare-disease-focused target, and it’s asking for board-meeting minutes and executive statements, too, Nikkei Asian Review reports.

Dubbing itself, “Thinking about Takeda's Bright Future," the group gave Takeda an Oct. 31 response deadline.

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

Takeda’s deal first faced opposition well before the two parties shook hands. In March, the company’s shares plummeted after it revealed its interest in Shire, in part because of questions surrounding the hefty debt necessary to pull the deal off.

RELATED: In revolt, Takeda family calls out CEO Weber over Shire deal

And since Takeda and Shire inked their pact back in May, more critics have joined the chorus. A descendent of Takeda’s founder publicly voiced his disapproval, predicting the takeover would prove detrimental to the Japanese drugmaker’s business. “Hasty decisions on big deals should be avoided. It will lead to disaster if there are large-scale mergers and acquisitions without careful consideration,” he said in September.

This isn’t the first time this particular shareholder group—which owns about 1% of the company, Nikkei says—has tried to pump the brakes on the Shire deal, either, Nikkei notes. During a June shareholder meeting, the group proposed a rule requiring that acquisitions of more than 1 trillion yen ($8.78 billion) win shareholder approval first. But the proposal garnered less than 10% support from shareholders.

RELATED: Takeda CEO reassures investors worried the math on its $62B Shire buyout doesn't add up

Takeda has defended its buyout decision and particularly worked to ward off concerns about its lagging hemophilia business. At a June meeting, Weber reassured investors that Takeda had already factored next-gen competition from Roche into its financial models for the company after Shire joins the fold.

Read more on

Suggested Articles

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.